STriTuVaD

In Silico Trial for Tuberculosis Vaccine Development - Project funded by the EU and DBT India #strituvad #insilicotrial #tuberculosis #insilicoTB

[STriTuVaD @STriTuVaD]

#insilicotrials aim to accelerate the development of a new #tuberculosis vaccine💉 our researchers are leveraging cutting-edge technology to fast-forward progress and tackle this global health challenge within Strituvad
Read more https://t.co/Uj6R2f4VKh

[VPH - The Society for In Silico Medicine @VPH_Society]

We're all set for the VPHi Summer School in Barcelona next week! 🌞📚
For live updates, behind-the-scenes moments, and stunning photos, follow our new Instagram account ➡️📸✨ @vphinstitute https://t.co/6kjdYla21Z

[Mimesis SRL @MimesisSrl]

Another day, another news! We've been selected among others innovative sicilian start-up to present Mimesis during the event "In.Sicily" that will be held in Palermo, on June 8. We can't wait to be there!

More info here: https://t.co/2ENgBZfvT4

[pJCardona💐🦠 @pjcardona14]

Thanks to #IAVI to organize this meeting on #tuberculosis #vaccines at the #SpanishHealthMinistry @ciberes @ArchivelFarma @TB_UITB @hgermanstrias @GTRecerca @tbexperimental @UMCiExp @TBVI_EU @STriTuVaD #TBworldDay

[COMBINE Group @COMBINE_Group]

𝐓𝐁𝐕𝐈 𝐩𝐚𝐫𝐭𝐧𝐞𝐫 𝐦𝐞𝐞𝐭𝐢𝐧𝐠
4 April 2023 - Les Diablerets (Switzerland)

#UISS #MycobacteriumTuberculosis #immunesystem #modelingandsimulation #insilicomedicine @STriTuVaD @TBVI_EU @unict_it @DsfsUnict

[COMBINE Group @COMBINE_Group]

Today 24th March is the #WorldTuberculosisDay

#insilicomedicine #UISS #digitaltwins #modelingandsimulation #stoptuberculosis #Ithemyc
@InSilicoWorld @STriTuVaD

[STriTuVaD @STriTuVaD]

In 2018 10mil people were found infected by #tuberculosis, with approximately 1.2 million deaths worldwide
"Moving forward through the #insilico modeling of tuberculosis: a further step with UISS-TB" presents a further step in UISS framework implementation
https://t.co/SHJzIicM3n

[STriTuVaD @STriTuVaD]

"Moving forward through the #insilico modeling of #tuberculosis: a further step with UISS-TB" is one of the Selected papers from the 3rd International Workshop on #Computational Methods for the Immune System Function (CMISF 2019)

Learn more 👇
https://t.co/JNkSOSKgEk

[STriTuVaD @STriTuVaD]

The simulation platform UISS-TB has been developed and fine-tuned through several years by the research group of the University of Catania and it is able to reproduce the human immune system response induced by #vaccines

Try it now 👇
https://t.co/JnmFnFVjlo

[STriTuVaD @STriTuVaD]

Partner UNICT also predicted, for every single patient, the AFB smear grade at time frame of the primary endpoint and at the end of the active phase.

[STriTuVaD @STriTuVaD]

[Pt1] The #insilico models generated by @unict_it have been used as input for the UISS computational modelling framework to predict the percentage of patients with sputum culture negative.

[STriTuVaD @STriTuVaD]

[Pt1] The #insilico models generated by @unict_it have been used as input for the UISS computational modelling framework to predict the percentage of patients with sputum culture negative.

[STriTuVaD @STriTuVaD]

UISS-TB computational modeling framework developed by @unict_it was used to generate #insilicomodels, in other words, the virtual patients to represent each individual enrolled in the Phase IIb Randomized Clinical Trial (RCT).

[STriTuVaD @STriTuVaD]

UISS-TB is a computational framework - developed by the University of Catania @unict_it - that makes use of a multi-scale, multi-organ, agent-based model (ABM) simulator of the immune system after the interaction with Mycobacterium Tuberculosis.

More 👇
https://t.co/Agh6oA7j8u

[STriTuVaD @STriTuVaD]

Towards the end of the project, the goal is to use the data collected from the Phase IIb Randomized Clinical Trial to generate the correspondent set of #insilicomodels for 140 profiles, 90 for drug-sensitive cohort and 50 for multi-drug resistant cohort
👇
https://t.co/IvgoPJHHPf

[STriTuVaD @STriTuVaD]

UISS-TB computational modeling framework developed by @unict_it was used to generate #insilicomodels, in other words, the virtual patients to represent each individual enrolled in the Phase IIb Randomized Clinical Trial (RCT).

[STriTuVaD @STriTuVaD]

Due to #COVID, TB notifications and case detection dropped and these estimated to have had a major impact on TB disease burden, reversing years of progress up to 2019. The global number of TB deaths is estimated to have increased in both 2020 and 2021 📈

[STriTuVaD @STriTuVaD]

@WHO published the 2022 Global #Tuberculosis Report that provides up-to-date assessment of the #TB epidemic and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels ➡️https://t.co/VciDHiuSRO

[STriTuVaD @STriTuVaD]

Computational modelling and simulation for immunotoxicity prediction induced by skin sensitisers - Check another application of the Universal Immune System Simulator @COMBINE_Group https://t.co/Dd5qTbwRco

[InSilicoWorld @InSilicoWorld]

#DNA mutations can occur spontaneously or can be induced by external factors such as electric fields, intercalators, radiations, etc.
The 27th @bio_comp e-seminar will focus on DNA Point Mutations in the Absence and Presence of Electric Fields

Register now ⬇️
#seminar #insilico

[STriTuVaD @STriTuVaD]

In the latest newsletter you can read a few words from our coordinator Dr Fichera from Etna Biotech srl - Read more ➡️ https://t.co/rMzHHXWlL4

[InSilicoWorld @InSilicoWorld]

What are the estimated #costs associated with bringing a novel therapeutic complex #medicaldevice to #market in the US?

This interesting paper shows that is not cheap...

Read it here 👇
https://t.co/cNQVwM9tRD